知柏地黄丸联合泼尼松治疗肾病综合征的效果及对血清PLA2R抗体、suPAR、sTREM-1表达的影响(1)
【摘要】 目的：探讨知柏地黄丸联合泼尼松治疗肾病综合征(NS)的效果及对血清抗磷脂酶A2受体(PLA2R)抗体、可溶性尿激酶型纤溶酶原激活物受体(suPAR)、可溶性髓样细胞触发受体-1(sTREM-1)表达的影响。方法：选取本院自2017年1月-2019年1月收治的93例肾病综合征患者，按照治疗方式的不同分为对照组(n=46)、观察组(n=47)。对照组给予泼尼松治疗，观察组在对照组基础上给予知柏地黄丸治疗。比较两组的疗效及实验室指标。结果：治疗后，观察组总有效率为93.62%，高于对照组的78.26%，差异有统计学意义(P<0.05)。治疗后，观察组24 h尿蛋白、血肌酐水平均低于对照组，血白蛋白高于对照组，差异均有统计学意义(P<0.05)。治疗后，观察组血清PLA2R抗体、suPAR、sTREM-1表达水平均低于对照组，差异均有统计学意义(P<0.05)。结论：知柏地黄丸联合泼尼松治疗肾病综合征效果显著，可改善肾功能，降低血清PLA2R抗体、suPAR、sTREM-1表达。
【关键词】 肾病综合征 知柏地黄丸 泼尼松 suPAR sTREM-1
[Abstract] Objective： To investigate the therapeutic effect of Zhibai Dihuang Pills combined with Prednisone on nephrotic syndrome (NS)， and its effect on the expression of serum anti-phospholipase A2 receptor (PLA2R) antibody， soluble urokinase-type plasminogen activatorreceptor (suPAR)， soluble triggering receptors expressed on myeloid cell-1 (sTREM-1). Method： A total of 93 patients with nephrotic syndrome admitted to our hospital from January 2017 to January 2019 were selected and divided into control group (n=46) and observation group (n=47) according to different treatment methods. The control group was treated with Prednisone， the observation group was treated with Zhibai Dihuang Pills on the basis of the control group. The efficacy and laboratory indexes of the two groups were compared. Result： After treatment， the total effective rate of the observation group was 93.62%， higher than 78.26% of the control group， the difference was statistically significant (P<0.05). After treatment， the levels of 24 h urine protein and serum creatinine of the observation group were lower than those of the control group， the serum albumin level of the observation group was higher than that of the control group， the differences were statistically significant (P<0.05). After treatment， the expression levels of serum PLA2R antibody， suPAR and sTREM-1 in the observation group were all lower than those in the control group， the differences were statistically significant (P<0.05). Conclusion： Zhibai Dihuang Pills combined with Prednisone is effective in treating nephrotic syndrome， which can improve renal function and reduce the expression of serum PLA2R antibody， suPAR and sTREM-1.
[Key words] Nephrotic syndrome Zhibai Dihuang Pills Prednisone suPAR sTREM-1
First-author’s address： Maternal and Child Health and Family Planning Service Center of Jiamusi， Jiamusi 154002， China
doi：10.3969/j.issn.1674-4985.2020.26.017
腎病综合征(NS)是以蛋白尿、低白蛋白血症、水肿、高血脂为主要表现的疾病，据国外报道，肾病综合征在普通人群中患病率约为2%[1]。泼尼松为糖皮质激素，是治疗肾病综合征的常用药物，具有一定的效果，然而长期单一使用糖皮质激素不良反应多。中医学将肾病综合征归为“水肿”“腰痛”“尿浊”等病证，为本虚标实之证，主张以滋阴补肾、清热泻火法治之。知柏地黄丸有滋阴清热的功效，是补肾经典方剂。本研究主要探讨知柏地黄丸联合泼尼松治疗肾病综合征的临床效果其对血清抗磷脂酶A2受体(anti-phospholipase A2 receptor，PLA2R)抗体、可溶性尿激酶型纤溶酶原激活物受体(soluble urokinase-type plasminogen activatorreceptor，suPAR)、可溶性髓样细胞触发受体-1(soluble triggering receptor expressed myeloid cells-1，sTREM-1)表达的影响。现报道如下。, 百拇医药(王莹)
【关键词】 肾病综合征 知柏地黄丸 泼尼松 suPAR sTREM-1
[Abstract] Objective： To investigate the therapeutic effect of Zhibai Dihuang Pills combined with Prednisone on nephrotic syndrome (NS)， and its effect on the expression of serum anti-phospholipase A2 receptor (PLA2R) antibody， soluble urokinase-type plasminogen activatorreceptor (suPAR)， soluble triggering receptors expressed on myeloid cell-1 (sTREM-1). Method： A total of 93 patients with nephrotic syndrome admitted to our hospital from January 2017 to January 2019 were selected and divided into control group (n=46) and observation group (n=47) according to different treatment methods. The control group was treated with Prednisone， the observation group was treated with Zhibai Dihuang Pills on the basis of the control group. The efficacy and laboratory indexes of the two groups were compared. Result： After treatment， the total effective rate of the observation group was 93.62%， higher than 78.26% of the control group， the difference was statistically significant (P<0.05). After treatment， the levels of 24 h urine protein and serum creatinine of the observation group were lower than those of the control group， the serum albumin level of the observation group was higher than that of the control group， the differences were statistically significant (P<0.05). After treatment， the expression levels of serum PLA2R antibody， suPAR and sTREM-1 in the observation group were all lower than those in the control group， the differences were statistically significant (P<0.05). Conclusion： Zhibai Dihuang Pills combined with Prednisone is effective in treating nephrotic syndrome， which can improve renal function and reduce the expression of serum PLA2R antibody， suPAR and sTREM-1.
[Key words] Nephrotic syndrome Zhibai Dihuang Pills Prednisone suPAR sTREM-1
First-author’s address： Maternal and Child Health and Family Planning Service Center of Jiamusi， Jiamusi 154002， China
doi：10.3969/j.issn.1674-4985.2020.26.017
腎病综合征(NS)是以蛋白尿、低白蛋白血症、水肿、高血脂为主要表现的疾病，据国外报道，肾病综合征在普通人群中患病率约为2%[1]。泼尼松为糖皮质激素，是治疗肾病综合征的常用药物，具有一定的效果，然而长期单一使用糖皮质激素不良反应多。中医学将肾病综合征归为“水肿”“腰痛”“尿浊”等病证，为本虚标实之证，主张以滋阴补肾、清热泻火法治之。知柏地黄丸有滋阴清热的功效，是补肾经典方剂。本研究主要探讨知柏地黄丸联合泼尼松治疗肾病综合征的临床效果其对血清抗磷脂酶A2受体(anti-phospholipase A2 receptor，PLA2R)抗体、可溶性尿激酶型纤溶酶原激活物受体(soluble urokinase-type plasminogen activatorreceptor，suPAR)、可溶性髓样细胞触发受体-1(soluble triggering receptor expressed myeloid cells-1，sTREM-1)表达的影响。现报道如下。, 百拇医药(王莹)